Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17787231 | 0.93 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL12623983 | 0.87 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL12624004 | 0.87 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL15693684 | 0.85 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL15693682 | 0.84 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL20365011 | 0.82 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL12624014 | 0.81 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL12622049 | 0.80 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL20787973 | 0.77 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL12627182 | 0.77 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | L3MBTL1 1789/4885ALDH1A1 4388/4885HCRTR1 2888/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | L3MBTL1 1789/4885ALDH1A1 4388/4885HCRTR1 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.